Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.53 |
| ▸ | PDE1A | P54750 | 1/20 | 0.53 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.53 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | UBE2N | P61088 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenethylline SCHEMBL121386 | 0.99 | ALDH1A1 (0.64) | ALDH1A1ADORA2BSMN1; SMN2RXFP1TSHR | |
| Fenethylline SCHEMBL155920 | 0.99 | ALDH1A1 (0.64) | ALDH1A1ADORA2BSMN1; SMN2RXFP1TSHR | |
| Fenethylline SCHEMBL1934850 | 0.96 | ALDH1A1 (0.60) | ALDH1A1ADORA2BSMN1; SMN2RXFP1TSHR | |
| Fenethylline SCHEMBL14057908 | 0.96 | ALDH1A1 (0.60) | ALDH1A1ADORA2BSMN1; SMN2RXFP1TSHR | |
| SCHEMBL684300 | 0.91 | ALDH1A1 (0.55) | ALDH1A1ADORA2BSMN1; SMN2RXFP1TSHR | |
| Fenethylline SCHEMBL28154439 | 0.91 | SMN1; SMN2 (0.55) | ALDH1A1ADORA2BSMN1; SMN2RXFP1TSHR | |
| SCHEMBL684285 | 0.90 | RXFP1 (0.53) | ALDH1A1ADORA2BSMN1; SMN2RXFP1TSHR | |
| SCHEMBL682774 | 0.89 | LMNA (0.66) | ALDH1A1ADORA2BSMN1; SMN2RXFP1TSHR | |
| SCHEMBL19036462 | 0.88 | ALDH1A1 (0.64) | ALDH1A1ADORA2BSMN1; SMN2RXFP1TSHR | |
| SCHEMBL683924 | 0.88 | SMN1; SMN2 (0.67) | ALDH1A1ADORA2BSMN1; SMN2RXFP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1577 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025027390-A2 | TECHNIQUES FOR FAVORING CARBON OXIDES ELECTROREDUCTION INTO ETHYLENE | TOTALENERGIES ONETECH (FR) | 2025-02-06 | — | — | WO | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| US-20240050408-A1 | USE OF MGLUR5 ANTAGONISTS FOR TREATING AMPHETAMINE ADDICTION | NOVARTIS AG (CH) | 2024-02-15 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| EP-4259126-A1 | USE OF MGLUR5 ANTAGONISTS FOR TREATING AMPHETAMINE ADDICTION | Novartis AG (CH) | 2023-10-18 | — | — | EP | claimed |
| EP-1165054-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | Pharmaquest Limited (BM) | 2002-01-02 | — | — | EP | claimed |
| US-6217904-B1 | MIXTURES; ADMINISTERING IN CYCLES | PHARMAQUEST LTD. (BM) | 2001-04-17 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000059479-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
| WO-2000059481-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0215697-B1 | ACYLCARNITINES AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL COMPARTMENTS | MERCK & CO. INC. (US) | 1992-03-25 | — | — | EP | claimed |
| EP-0214898-B1 | CHOLINE ESTERS AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL CAVITIES | MERCK & CO. INC. (US) | 1992-03-11 | — | — | EP | claimed |
| EP-0215697-A2 | Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments | MERCK & CO. INC. (US) | 1987-03-25 | — | — | EP | claimed |
| EP-0214898-A2 | Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities | MERCK & CO. INC. (US) | 1987-03-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | ALDH1A1 687/4885ADORA2B 46/4885SMN1; SMN2 673/4885 |
| US-20240050408-A1 | USE OF MGLUR5 ANTAGONISTS FOR TREATING AMPHETAMINE ADDICTION | GRM5, TAAR5, GRM4 | ALDH1A1 670/4885ADORA2B 211/4885SMN1; SMN2 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.